Normal view MARC view ISBD view

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

MedStar author(s):

Citation: Annals of Oncology. 31(2):171-190, 2020 02.PMID: 31959335Institution: MedStar Heart & Vascular InstitutenaForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antineoplastic Agents | *Heart Diseases | *Neoplasms | Antineoplastic Agents/ae [Adverse Effects] | Consensus | Heart Diseases/ci [Chemically Induced] | Heart Diseases/ep [Epidemiology] | Humans | Medical Oncology | Neoplasms/co [Complications] | Neoplasms/dt [Drug Therapy] | Neoplasms/ep [Epidemiology]Year: 2020 Local holdings: Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1999 - 2006ISSN:

0923-7534

Name of journal: Annals of oncology : official journal of the European Society for Medical OncologyAbstract: Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis. Copyright (c) 2019 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.All authors: Armenian S, Barac A, Blaes A, Calabro MG, Cardinale D, Carver J, Cipolla CM, Curigliano G, de Azambuja E, DeCara J, Dent S, ESMO Guidelines Committee. Electronic address: [email protected], Fradley M, Ganatra S, Harrison E, Herrmann J, Iakobishvili Z, Jordan K, Krone R, Ky B, Lancellotti P, Lenihan D, Lyon AR, Mitchell J, Moslehi J, Orecchia R, Patel A, Porter C, Witteles R, Zamorano JLOriginally published: Annals of Oncology. 31(2):171-190, 2020 Feb.Fiscal year: FY2020Digital Object Identifier:

https://dx.doi.org/10.1016/j.annonc.2019.10.023

Date added to catalog: 2020-02-10

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	31959335	Available		31959335

Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1999 - 2006

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis. Copyright (c) 2019 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

English